U.S. GYNECOLOGY, CLINICIAN SURVEY

224 Pages | 105 Exhibits | 2000 Analysis

OVERVIEW:
Gynecology encompasses a variety of medical concerns, conditions, and procedures that approach the horizontal scope of primary care--many women consider their gynecologist to be their primary care physician--while simultaneously providing the vertical depth of a specialty via its interventional caseloads. With both the scope of services offered and large number of practitioners, gynecologists make an attractive target for medical companies.

This report from Medtech Insight provides clients with primary research information obtained from more than 200 gynecologists concerning their current gynecologic practices, familiarity with products and suppliers, planned product/equipment purchases, trends in service offerings, and factors impacting the adoption of new technologies and procedures.

Key results presented in this report, which provides in-depth analysis of specific findings and contains more than 100 exhibits, include the surveyed gynecologists' identification of the medical companies with which they most often personally interact and their ratings concerning the quality of that interaction.

Major topics include: survey respondent background information; menorrhagia management; urogynecology; osteoporosis management; and general issues of interest to manufacturers.

TABLE OF CONTENTS:

EXECUTIVE SUMMARY

     i. Respondent Background

     ii. Trends in Menorrhagia Management

     iii. Trends in Urogynecology

     iv. Trends in Osteoporosis Diagnosis and Management

     v. General Issues

 

1. BACKGROUND

     1.1 Respondents

          1.1.1 By Age

          1.1.2 By Geographic Region

          1.1.3 By Practice Type

          1.1.4 By Practice Ownership

          1.1.5 By Practice Volume and Distribution

          1.1.6 By Urogynecology Caseloads

          1.1.7 By Menopause Caseloads

 

2. TRENDS IN MENORRHAGIA MANAGEMENT

     2.1 Menorrhagia Treatment Ratings

     2.2 Planned Use of Menorrhagia Treatments

     2.3 Obstacles to Operative Hysteroscopy

 

3. TRENDS IN UROGYNECOLOGY

     3.1 Effectiveness of Stress Incontinence Therapies

     3.2 Planned Use of Stress Incontinence Therapies

     3.3 Obstacles to Treatment of Female Urological Conditions

     3.4 Current and Planned Ownership of Urodynamic Equipment

     3.5 Effectiveness of Urge Incontinence Therapies

     3.6 Planned Use of Urge Incontinence Therapies

 

4. TRENDS IN OSTEOPOROSIS DIAGNOSIS AND MANAGEMENT

     4.1 Osteoporosis Screening Trends

     4.2 Obstacles to Office-Based Densitometry

     4.3 Value of Densitometry and Biochemical Markers

     4.4 Current and Planned Ownership of Office Densitometry
           Equipment

     4.5 Osteoporosis Treatment Ratings

     4.6 Planned Use of Osteoporosis Treatments

 

5. GENERAL ISSUES

     5.1 Factors Currently Impacting the Adoption of New Technology

     5.2 The Impact of Clinical Developments

     5.3 Interaction with Medical Device Companies

 

APPENDIX A:  COMPANY LISTING

APPENDIX B:  DISTRIBUTION OF STATES AMONG GEOGRAPHIC
                         REGIONS

APPENDIX C:  SURVEY ON MENORRHAGIA, UROGYNECOLOGY,
                       
 AND OSTEOPOROSIS

 

LIST OF EXHIBITS

 

Exhibit 1-1:    Distribution of Respondents, by Age 

Exhibit 1-2:    Distribution of Respondents and Obstetricians/ Gynecologists, by Region 

Exhibit 1-3:    Distribution of Respondents, by Practice Type 

Exhibit 1-4:    Average Number of Physicians in Group Practices, by Type and Region 

Exhibit 1-5:    Distribution of Respondents, by Practice Ownership 

Exhibit 1-6:    Weekly Patient Volumes, All Respondents 

Exhibit 1-7:    Weekly Patient Volumes, by Respondent Age 

Exhibit 1-8:    Weekly Patient Volumes, by Respondent Practice Type 

Exhibit 1-9:    Weekly Patient Volumes, by Respondent Region 

Exhibit 1-10:  Distribution of Respondents, by Total Weekly Patient Volume 

Exhibit 1-11:  Average Practice Distribution, All Respondents, 1999 and 2001 

Exhibit 1-12:  Average Practice Distribution, by Age, 1999 and 2001 

Exhibit 1-13:  Average Practice Distribution, by Practice Type, 1999 and 2001 

Exhibit 1-14:  Average Practice Distribution, by Region, 1999 and 2001 

Exhibit 1-15:  Distribution of Respondents, by Weekly Urogynecology Patient Volume 

Exhibit 1-16:  Distribution of Respondents, by Weekly Menopause Patient Volume 

Exhibit 1-17:  Distribution of Respondents, by Age and Menopause Caseload 

 

Exhibit 2-1:    Rating and Knowledge of Menorrhagia Management Approaches, All Respondents 

Exhibit 2-2:    Rating and Knowledge of Menorrhagia Management Approaches, by Age 

Exhibit 2-3:    Rating and Knowledge of Menorrhagia Management Approaches, by Total Patient Volume 

Exhibit 2-4:    Rating and Knowledge of Menorrhagia Management Approaches, by Geographic Region 

Exhibit 2-5:    Rating and Knowledge of Menorrhagia Management Approaches, by Practice Type 

Exhibit 2-6:    Planned Use of Menorrhagia Management Approaches, All Respondents 

Exhibit 2-7:    Planned Use of Hysteroscopic Ablation/Resection, by Subcategories of Respondents 

Exhibit 2-8:    Planned Use of Office Thermal Balloon Ablation, by Subcategories of Respondents 

Exhibit 2-9:    Planned Use of Office Cryoablation, by Subcategories of Respondents 

Exhibit 2-10:  Planned Use of Office Microwave Ablation, by Subcategories of Respondents 

Exhibit 2-11:  Planned Use of Uterine Artery Embolization, by Subcategories of Respondents 

Exhibit 2-12:  Obstacles to Widespread Performance of Operative Hysteroscopy 

Exhibit 2-13:  Concern Regarding Fluid Overload as an Obstacle to Operative Hysteroscopy 

Exhibit 2-14:  Inadequate Instrumentation as an Obstacle to Operative Hysteroscopy 

Exhibit 2-15:  Difficulty of Technique as an Obstacle to Operative Hysteroscopy 

Exhibit 2-16:  Lack of Training as an Obstacle to Operative Hysteroscopy 

Exhibit 2-17:  Insufficient Indications as an Obstacle to Operative Hysteroscopy 

Exhibit 2-18:  Obstacles to Operative Hysteroscopy, by Performance Plans 

 

Exhibit 3-1:    Rating and Knowledge of Stress Urinary Incontinence Management Approaches, All Respondents 

Exhibit 3-2:    Rating and Knowledge of Stress Urinary Incontinence Management Approaches, by Age 

Exhibit 3-3:    Rating and Knowledge of Stress Urinary Incontinence Management Approaches, by Urogynecology Caseload 

Exhibit 3-4:    Rating and Knowledge of Stress Urinary Incontinence Management Approaches, by Geographic Region 

Exhibit 3-5:    Planned Use of Stress Incontinence Management Approaches, All Respondents 

Exhibit 3-6:    Planned Use of Major Surgery, by Subcategories of Respondents 

Exhibit 3-7:    Planned Use of Minimally Invasive Surgery, by Subcategories of Respondents 

Exhibit 3-8:    Planned Use of Collagen Bulking Agents, by Subcategories of Respondents 

Exhibit 3-9:    Planned Use of Nonabsorbable Bulking Agents, by Subcategories of Respondents 

Exhibit 3-10:  Planned Use of Urethral Prostheses and Inserts, by Subcategories of Respondents 

Exhibit 3-11:  Planned Use of Pelvic Exercisers, by Subcategories of Respondents 

Exhibit 3-12:  Planned Use of Extracorporeal Magnetic Innervation, by Subcategories of Respondents 

Exhibit 3-13:  Obstacles to Treatment of Female Urological Conditions 

Exhibit 3-14:  Practice Focus or Expertise as Obstacle to Treatment of Urological Conditions 

Exhibit 3-15:  Cystoscopy Credentialing as Obstacle to Treatment of Urological Conditions 

Exhibit 3-16:  Lack of Effective Options as Obstacle to Treatment of Urological Conditions 

Exhibit 3-17:  Difficulty Making a Definitive Diagnosis as Obstacle to Treatment of Urological Conditions 

Exhibit 3-18:  Poor Patient Compliance as an Obstacle to Treatment of Urological Conditions 

Exhibit 3-19:  Acquisition Plans for Office-Based Urodynamic Equipment 

Exhibit 3-20:  Urodynamic Systems Owned and Being Purchased 

Exhibit 3-21:  Rating and Knowledge of Urge Incontinence Management Approaches, All Respondents 

Exhibit 3-22:  Rating and Knowledge of Urge Incontinence Management Approaches, by Age 

Exhibit 3-23:  Rating and Knowledge of Urge Incontinence Management Approaches, by Urogynecology Caseload 

Exhibit 3-24:  Rating and Knowledge of Urge Incontinence Management Approaches, by Geographic Region 

Exhibit 3-25:  Planned Use of Urge Incontinence Management Approaches, All Respondents 

Exhibit 3-26:  Planned Use of Ditropan XL, by Subcategories of Respondents 

Exhibit 3-27:  Planned Use of Detrol, by Subcategories of Respondents 

Exhibit 3-28:  Planned Use of Other Drugs, by Subcategories of Respondents 

Exhibit 3-29:  Planned Use of Pelvic Nerve Stimulation, by Subcategories of Respondents 

Exhibit 3-30:  Planned Use of Afferent or Ankle Nerve Stimulation, by Subcategories of Respondents 

 

Exhibit 4-1:    Average Monthly Densitometry Screening by Site, All Respondents, 1999 and 2001 

Exhibit 4-2:    Average Monthly Densitometry Screenings, by Site and Age, 1999 and 2001 

Exhibit 4-3:    Average Monthly Densitometry Screenings, by Site and Menopause Caseload, 1999 and 2001 

Exhibit 4-4:    Average Monthly Densitometry Screenings, by Site and Geographic Region, 1999 and 2001 

Exhibit 4-5:    Average Monthly Densitometry Screenings, by Site and Practice Type, 1999 and 2001 

Exhibit 4-6:    Obstacles to More Widespread Office-Based Densitometry 

Exhibit 4-7:    Existing Hormone Replacement Therapy as an Obstacle to Widespread Office Densitometry 

Exhibit 4-8:    Lack of Effective Treatment Options for Osteoporosis as an Obstacle to Widespread Office Densitometry 

Exhibit 4-9:    Credentialing Requirements as an Obstacle to Widespread Office Densitometry 

Exhibit 4-10:  Routine Screening Not Reimbursed as an Obstacle to Widespread Office Densitometry 

Exhibit 4-11:  Cost of Densitometry Equipment as an Obstacle to Widespread Office Densitometry 

Exhibit 4-12:  Lack of American College of Obstetrics and Gynecology Endorsement as an Obstacle to Widespread Office Densitometry 

Exhibit 4-13:  Perceived Value of Densitometry and Biochemical Markers for Osteoporosis, All Respondents 

Exhibit 4-14:  Perceived Value of Densitometry and Biochemical Markers for Osteoporosis, by Age 

Exhibit 4-15:  Perceived Value of Densitometry and Biochemical Markers for Osteoporosis, by Menopause Caseload 

Exhibit 4-16:  Perceived Value of Densitometry and Biochemical Markers for Osteoporosis, by Geographic Region 

Exhibit 4-17:  Acquisition Plans for Densitometry Systems Equipment 

Exhibit 4-18:  Densitometry Systems Owned and Being Purchased 

Exhibit 4-19:  Rating and Knowledge of Osteoporosis Management Approaches, All Respondents 

Exhibit 4-20:  Rating and Knowledge of Osteoporosis Management Approaches, by Age 

Exhibit 4-21:  Rating and Knowledge of Osteoporosis Management Approaches, by Menopause Caseload 

Exhibit 4-22:  Rating and Knowledge of Osteoporosis Management Approaches, by Geographic Region 

Exhibit 4-23:  Planned Use of Osteoporosis Management Approaches, All Respondents 

Exhibit 4-24:  Planned Use of Hormone Replacement Therapy, by Subcategories of Respondents 

Exhibit 4-25:  Planned Use of Selective Estrogen Receptor Modulators, by Subcategories of Respondents 

Exhibit 4-26:  Planned Use of Bisphosphonates, by Subcategories of Respondents 

Exhibit 4-27:  Planned Use of Calcitonins, by Subcategories of Respondents 

Exhibit 4-28:  Planned Use of Bone Synthesis Drugs, by Subcategories of Respondents 

 

Exhibit 5-1:    Average Ratings of Factors Influencing New Technologies and Procedures, All Respondents 

Exhibit 5-2:    Average Ratings of Factors Influencing Technologies and Procedures, by Age 

Exhibit 5-3:    Average Ratings of Factors Influencing Technologies and Procedures, by Total Caseload 

Exhibit 5-4:    Average Ratings of Factors Influencing Technologies and Procedures, by Geographic Region 

Exhibit 5-5:    Average Ratings of Factors Influencing Technologies and Procedures, by Practice Type 

Exhibit 5-6:    Important Developments in Obstetrics and Gynecology Through 2001, by Respondent Mentions 

Exhibit 5-7:    Important Developments in Obstetrics and Gynecology Through 2001, by Clinical Area 

Exhibit 5-8:    Gynecologist Interactions with Medical Device Companies, by Respondent Share of Mentions and Average Ratings

 



COMPANIES COVERED:

Contact Us

Need help finding medtech research? Let us help you!